KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Current Assets (2017 - 2026)

Amneal Pharmaceuticals has reported Current Assets over the past 9 years, most recently at $1.9 billion for Q4 2025.

  • For Q4 2025, Current Assets rose 20.37% year-over-year to $1.9 billion; the TTM value through Dec 2025 reached $1.9 billion, up 20.37%, while the annual FY2025 figure was $1.9 billion, 20.37% up from the prior year.
  • Current Assets for Q4 2025 was $1.9 billion at Amneal Pharmaceuticals, up from $1.8 billion in the prior quarter.
  • Over five years, Current Assets peaked at $1.9 billion in Q4 2025 and troughed at $1.3 billion in Q1 2023.
  • A 5-year average of $1.5 billion and a median of $1.5 billion in 2024 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: dropped 12.07% in 2021 and later increased 21.49% in 2025.
  • Year by year, Current Assets stood at $1.5 billion in 2021, then decreased by 7.12% to $1.4 billion in 2022, then fell by 2.41% to $1.4 billion in 2023, then rose by 15.24% to $1.6 billion in 2024, then grew by 20.37% to $1.9 billion in 2025.
  • Business Quant data shows Current Assets for AMRX at $1.9 billion in Q4 2025, $1.8 billion in Q3 2025, and $1.6 billion in Q2 2025.